Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.
Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness via pulse wave velocity (PWV), UACR, endothelial glycocalyx via Microscan camera, and global longitudinal strain via echocardiography will be assesed at baseline, 4 and 12 months after treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
60
Combined treatment with dulaglutide and dapagliflozin
DPP-4i treatment as an add-on to metformin
Attikon University General Hospital
Chaïdári, Attica, Greece
UACR
UACR change after 4 and 12 months of treatment
Time frame: 4 and 12 months
PWV
PWV change after 4 and 12 months of treatment
Time frame: 4 and 12 months
PBR
PBR change after 4 and 12 months of treatment
Time frame: 4 and 12 months
GLS
GLS change after 4 and 12 months of ttreatment
Time frame: 4 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.